Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 1h-pyrrole-3-methanamine, 5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-n-methyl-
2. 5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-n-methyl-1h-pyrrole-3-methanamine
3. Dwp-14012
4. Dwp14012
5. Fexuprazan
1. Fexuprazan
2. 1902954-60-2
3. Dwp14012
4. Dwp-14012
5. Be52s2c1qt
6. 1-[5-(2,4-difluorophenyl)-1-(3-fluorobenzene-1-sulfonyl)-4-methoxy-1h-pyrrol-3-yl]-n-methylmethanamine
7. 1h-pyrrole-3-methanamine, 5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-n-methyl-
8. 5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-n-methyl-1h-pyrrole-3-methanamine
9. Abeprazan [inn]
10. Fexuprazan [inn]
11. Unii-be52s2c1qt
12. Chembl4594445
13. Schembl18196939
14. Glxc-25721
15. Hy-109079
16. Cs-0039254
17. 1-[5-(2,4-difluorophenyl)-1-(3-fluorophenyl)sulfonyl-4-methoxypyrrol-3-yl]-n-methylmethanamine
Molecular Weight | 410.4 g/mol |
---|---|
Molecular Formula | C19H17F3N2O3S |
XLogP3 | 3.2 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 6 |
Exact Mass | 410.09119807 g/mol |
Monoisotopic Mass | 410.09119807 g/mol |
Topological Polar Surface Area | 68.7 Ų |
Heavy Atom Count | 28 |
Formal Charge | 0 |
Complexity | 618 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Gastrointestinal Agents
Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion. (See all compounds classified as Gastrointestinal Agents.)
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
China's leading API and intermediate manufacturer, offering CMO/CDMO services and exports to 70+ countries, enhancing global health.
ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.
Registrant Name : Daewoong Bio Co., Ltd.
Registration Date : 2021-12-30
Registration Number : 1632-3-ND
Manufacturer Name : Daewoong Bio Co., Ltd.
Manufacturer Address : 29, Jaehakdanji-ro, Hyangnam-eup, Hwaseong-si, Gyeonggi-do
Registrant Name : Daewoong Bio Co., Ltd.
Registration Date : 2021-12-30
Registration Number : 1632-3-ND
Manufacturer Name : Daewoong Bio Co., Ltd.
Manufacturer Address : 29, Jaehakdanji-ro, Hyangnam-eup, Hwaseong-si, Gyeonggi-do
Details:
Fexuclue (fexuprazan HCl), a novel potassiumcompetitive acid blocker (PCAB), is approved as a new treatment for adults with Erosive Esophagitis of all grades.
Lead Product(s): Fexuprazan,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Fexuclue
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Daewoong Pharmaceutical
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 07, 2025
Lead Product(s) : Fexuprazan,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Daewoong Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Sun Pharma Launches Medication for Erosive Esophagitis
Details : Fexuclue (fexuprazan HCl), a novel potassiumcompetitive acid blocker (PCAB), is approved as a new treatment for adults with Erosive Esophagitis of all grades.
Product Name : Fexuclue
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 07, 2025
Details:
DWP14012 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Helicobacter Infections.
Lead Product(s): Fexuprazan,Amoxicillin Trihydrate,Clarithromycin
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: iNtherapeutics
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 27, 2024
Lead Product(s) : Fexuprazan,Amoxicillin Trihydrate,Clarithromycin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : iNtherapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DWP14012 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Helicobacter Infections.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 27, 2024
Details:
DWP14012 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Fexuprazan,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 18, 2024
Lead Product(s) : Fexuprazan,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DWP14012 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 18, 2024
Details:
Fexuprazan is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Gastroesophageal Reflux.
Lead Product(s): Fexuprazan,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 31, 2024
Lead Product(s) : Fexuprazan,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Fexuprazan is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Gastroesophageal Reflux.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 31, 2024
Details:
DWP14012 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Non-Erosive Reflux Disease.
Lead Product(s): Fexuprazan,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 08, 2023
Lead Product(s) : Fexuprazan,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DWP14012 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Non-Erosive Reflux Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 08, 2023
Details:
Under the agreement, Daewoong Pharmaceutical plans to expand its presence of a potassium-competitive acid blocker (P-CAB) drug Fexuclue (fexuprazan) in the African pharmaceutical market for gastroesophageal reflux disease (GERD).
Lead Product(s): Fexuprazan,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Fexuclue
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: COOPER PHARMA
Deal Size: $20.3 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 26, 2023
Lead Product(s) : Fexuprazan,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : COOPER PHARMA
Deal Size : $20.3 million
Deal Type : Licensing Agreement
Details : Under the agreement, Daewoong Pharmaceutical plans to expand its presence of a potassium-competitive acid blocker (P-CAB) drug Fexuclue (fexuprazan) in the African pharmaceutical market for gastroesophageal reflux disease (GERD).
Product Name : Fexuclue
Product Type : Miscellaneous
Upfront Cash : Undisclosed
July 26, 2023
Details:
Under the terms of the termination agreement, Daewoong regains all rights to the commercialization and clinical development of Fexuclue (fexuprazan), a novel potassium-competitive acid blocker for the treatment of erosive esophagitis, in the U.S. and Canada.
Lead Product(s): Fexuprazan,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Fexuclue
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Neurogastrx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination June 05, 2023
Lead Product(s) : Fexuprazan,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Neurogastrx
Deal Size : Undisclosed
Deal Type : Termination
Details : Under the terms of the termination agreement, Daewoong regains all rights to the commercialization and clinical development of Fexuclue (fexuprazan), a novel potassium-competitive acid blocker for the treatment of erosive esophagitis, in the U.S. and Can...
Product Name : Fexuclue
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 05, 2023
Details:
DWP14012 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Esophagitis, Peptic.
Lead Product(s): Fexuprazan,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 14, 2023
Lead Product(s) : Fexuprazan,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
The Efficacy and Safety of DWP14012 in Chinese Patients With Reflux Esophagitis
Details : DWP14012 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Esophagitis, Peptic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 14, 2023
Details:
DWP14012 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Fexuprazan,DWC202201
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 13, 2023
Lead Product(s) : Fexuprazan,DWC202201
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DWP14012 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 13, 2023
Details:
Fexuclue (fexuprazan) is a potassium-competitive acid blocker (P-CAB) drug. By improving the drawbacks of existing proton pump inhibitors (PPIs), it binds to the proton pump without activating gastric acid and quickly and stably inhibits the secretion of gastric acid.
Lead Product(s): Fexuprazan,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Fexuclue
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 25, 2023
Lead Product(s) : Fexuprazan,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Fexuclue (fexuprazan) is a potassium-competitive acid blocker (P-CAB) drug. By improving the drawbacks of existing proton pump inhibitors (PPIs), it binds to the proton pump without activating gastric acid and quickly and stably inhibits the secretion of...
Product Name : Fexuclue
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 25, 2023
methyl 5-(2,4-difluorophenyl)-4- methoxy-1H-pyrrol...
CAS Number : 1902955-29-6
End Use API : Fexuprazan
About The Company : Shandong Chenghui Shuangda Pharmaceutical Co., Ltd. specializes in R&D and production of APIs and advanced intermediates, CDMO/CRO/OEM, and Technology Transfer ...
3-Fluorobenzenesulfonyl chloride
CAS Number : 701-27-9
End Use API : Fexuprazan
About The Company : Shandong Chenghui Shuangda Pharmaceutical Co., Ltd. specializes in R&D and production of APIs and advanced intermediates, CDMO/CRO/OEM, and Technology Transfer ...
CAS Number : 701-27-9
End Use API : Fexuprazan
About The Company : Founded in 2006, ChemExpress specializes in offering CRO & CDMO services for pharmaceutical and biotech companies, focusing on small molecules, biologics and ne...
CAS Number : 2258638-53-6
End Use API : Fexuprazan
About The Company : Founded in 2006, ChemExpress specializes in offering CRO & CDMO services for pharmaceutical and biotech companies, focusing on small molecules, biologics and ne...
CAS Number : 2258638-52-5
End Use API : Fexuprazan
About The Company : Founded in 2006, ChemExpress specializes in offering CRO & CDMO services for pharmaceutical and biotech companies, focusing on small molecules, biologics and ne...
5-(2-Fluorophenyl)-1H-pyrrole-3-carboxaldehyde
CAS Number : 1902955-29-6
End Use API : Fexuprazan
About The Company : Equilife Laboratories Pvt. Ltd. is an India-based pharmaceutical company, specializing in innovative process development for pharmaceutical products and service...
methyl 5-(2,4-difluorophenyl)-4-methoxy-1H-pyrrole...
CAS Number : 1902955-29-6
End Use API : Fexuprazan
About The Company : Sunway Pharm ltd provides high quality building blocks to the global pharmaceutical and bio-technology industry. Combining our chemistry expertise and our econo...
3-fluorobenzene-1-sulfonyl chloride
CAS Number : 701-27-9
End Use API : Fexuprazan
About The Company : We introduce ourselves as manufacturer of Active Pharmaceutical Ingredients (API) and intermediates with a professional approach that is aimed at finest results...
ABOUT THIS PAGE
56
PharmaCompass offers a list of Fexuprazan API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Fexuprazan manufacturer or Fexuprazan supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Fexuprazan manufacturer or Fexuprazan supplier.
PharmaCompass also assists you with knowing the Fexuprazan API Price utilized in the formulation of products. Fexuprazan API Price is not always fixed or binding as the Fexuprazan Price is obtained through a variety of data sources. The Fexuprazan Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Fexuprazan manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Fexuprazan, including repackagers and relabelers. The FDA regulates Fexuprazan manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Fexuprazan API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Fexuprazan manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Fexuprazan supplier is an individual or a company that provides Fexuprazan active pharmaceutical ingredient (API) or Fexuprazan finished formulations upon request. The Fexuprazan suppliers may include Fexuprazan API manufacturers, exporters, distributors and traders.
click here to find a list of Fexuprazan suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Fexuprazan Drug Master File in Korea (Fexuprazan KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Fexuprazan. The MFDS reviews the Fexuprazan KDMF as part of the drug registration process and uses the information provided in the Fexuprazan KDMF to evaluate the safety and efficacy of the drug.
After submitting a Fexuprazan KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Fexuprazan API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Fexuprazan suppliers with KDMF on PharmaCompass.
Fexuprazan Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Fexuprazan GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Fexuprazan GMP manufacturer or Fexuprazan GMP API supplier for your needs.
A Fexuprazan CoA (Certificate of Analysis) is a formal document that attests to Fexuprazan's compliance with Fexuprazan specifications and serves as a tool for batch-level quality control.
Fexuprazan CoA mostly includes findings from lab analyses of a specific batch. For each Fexuprazan CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Fexuprazan may be tested according to a variety of international standards, such as European Pharmacopoeia (Fexuprazan EP), Fexuprazan JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Fexuprazan USP).